Literature DB >> 27455994

Rethinking Nuclear Receptors as Potential Therapeutic Targets for Retinal Diseases.

Mayur Choudhary1, Goldis Malek1,2.   

Abstract

Collectively, retinal diseases, including age-related macular degeneration, retinitis pigmentosa, and diabetic retinopathy, result in severe vision impairment worldwide. The absence and/or limited availability of successful drug therapies for these blinding disorders necessitates further understanding their pathobiology and identifying new targetable signaling pathways. Nuclear receptors are transcription regulators of many key aspects of human physiology, as well as pathophysiology, with reported roles in development, aging, and disease. Some of the pathways regulated by nuclear receptors include, but are not limited to, angiogenesis, inflammation, and lipid metabolic dysregulation, mechanisms also important in the initiation and development of several retinal diseases. Herein, we present an overview of the biology of three diseases affecting the posterior eye, summarize a growing body of evidence that suggests direct or indirect involvement of nuclear receptors in disease progression, and discuss the therapeutic potential of targeting nuclear receptors for treatment.

Entities:  

Keywords:  age-related macular degeneration; diabetic retinopathy; nuclear receptors; retinal diseases; retinitis pigmentosa

Mesh:

Substances:

Year:  2016        PMID: 27455994      PMCID: PMC5586077          DOI: 10.1177/1087057116659856

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  130 in total

Review 1.  Signalling through nuclear receptors.

Authors:  Jamshed R Tata
Journal:  Nat Rev Mol Cell Biol       Date:  2002-09       Impact factor: 94.444

Review 2.  Principles for modulation of the nuclear receptor superfamily.

Authors:  Hinrich Gronemeyer; Jan-Ake Gustafsson; Vincent Laudet
Journal:  Nat Rev Drug Discov       Date:  2004-11       Impact factor: 84.694

3.  Identification of potent agonists of photoreceptor-specific nuclear receptor (NR2E3) and preparation of a radioligand.

Authors:  Scott E Wolkenberg; Zhijian Zhao; Marianna Kapitskaya; Andrea L Webber; Konstantin Petrukhin; Yui Sing Tang; Dennis C Dean; George D Hartman; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2006-08-01       Impact factor: 2.823

4.  Modulation of VEGF-induced retinal vascular permeability by peroxisome proliferator-activated receptor-β/δ.

Authors:  Sandra Suarez; Gary W McCollum; Colin A Bretz; Rong Yang; Megan E Capozzi; John S Penn
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-11-18       Impact factor: 4.799

5.  Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding.

Authors:  P Escher; O Braissant; S Basu-Modak; L Michalik; W Wahli; B Desvergne
Journal:  Endocrinology       Date:  2001-10       Impact factor: 4.736

6.  Excess cone cell proliferation due to lack of a functional NR2E3 causes retinal dysplasia and degeneration in rd7/rd7 mice.

Authors:  N B Haider; J K Naggert; P M Nishina
Journal:  Hum Mol Genet       Date:  2001-08-01       Impact factor: 6.150

Review 7.  Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch's membrane/choriocapillaris complex.

Authors:  Imran Bhutto; Gerard Lutty
Journal:  Mol Aspects Med       Date:  2012-04-21

8.  Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments.

Authors:  David B Rein; John S Wittenborn; Xinzhi Zhang; Amanda A Honeycutt; Sarah B Lesesne; Jinan Saaddine
Journal:  Arch Ophthalmol       Date:  2009-04

9.  Liver X receptor activation decreases the severity of experimental autoimmune encephalomyelitis.

Authors:  Claudia Hindinger; David R Hinton; Stefanie J Kirwin; Roscoe D Atkinson; Margaret E Burnett; Cornelia C Bergmann; Stephen A Stohlman
Journal:  J Neurosci Res       Date:  2006-11-01       Impact factor: 4.164

10.  Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand.

Authors:  Laura A Solt; Naresh Kumar; Philippe Nuhant; Yongjun Wang; Janelle L Lauer; Jin Liu; Monica A Istrate; Theodore M Kamenecka; William R Roush; Dušica Vidović; Stephan C Schürer; Jihong Xu; Gail Wagoner; Paul D Drew; Patrick R Griffin; Thomas P Burris
Journal:  Nature       Date:  2011-04-17       Impact factor: 49.962

View more
  6 in total

1.  Suppression of aberrant choroidal neovascularization through activation of the aryl hydrocarbon receptor.

Authors:  Mayur Choudhary; Stephen Safe; Goldis Malek
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-02-23       Impact factor: 5.187

2.  Bulk and single-cell gene expression analyses reveal aging human choriocapillaris has pro-inflammatory phenotype.

Authors:  Andrew P Voigt; S Scott Whitmore; Kelly Mulfaul; Kathleen R Chirco; Joseph C Giacalone; Miles J Flamme-Wiese; Adam Stockman; Edwin M Stone; Budd A Tucker; Todd E Scheetz; Robert F Mullins
Journal:  Microvasc Res       Date:  2020-06-09       Impact factor: 3.514

Review 3.  Leveraging Nuclear Receptors as Targets for Pathological Ocular Vascular Diseases.

Authors:  Pei-Li Yao; Jeremy Peavey; Goldis Malek
Journal:  Int J Mol Sci       Date:  2020-04-21       Impact factor: 5.923

Review 4.  Small-Molecule Modulation of PPARs for the Treatment of Prevalent Vascular Retinal Diseases.

Authors:  Xiaozheng Dou; Adam S Duerfeldt
Journal:  Int J Mol Sci       Date:  2020-12-04       Impact factor: 5.923

5.  Evaluation of the possibility of selective modulation of retinal glucose transporters in diabetic complications: An experimental study.

Authors:  Kanuj Mishra; Madhu Nath; Nabanita Halder; Thirumurthy Velpandian
Journal:  Indian J Pharmacol       Date:  2020 Nov-Dec       Impact factor: 1.200

6.  Biliverdin regulates NR2E3 and zebrafish retinal photoreceptor development.

Authors:  Blaine Connor; Kayla Titialii-Torres; Abigail E Rockenhaus; Samuel Passamonte; Ann C Morris; Young-Sam Lee
Journal:  Sci Rep       Date:  2022-05-04       Impact factor: 4.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.